Hepatoblastoma, a rare embryonic tumor that may arise sporadically or in the context of hereditary syndromes (familial adenomatous polyposis and Beckwith-Wiedemann's) is the most frequent liver cancer of childhood. Deregulation of the APC/b-catenin pathway occurs in a consistent fraction of hepatoblastomas, with mutations in the APC and b-catenin genes implicated in familial adenomatous polyposis-associated and sporadic hepatoblastomas, respectively. Alterations in other cancer-related molecular pathways have not been reported. We investigated a series of 21 sporadic paraffin-embedded hepatoblastoma cases for mutations in the p53 (exons 5-8) and b-catenin (exon 3) genes, loss of heterozygosity at APC, microsatellite instability and immunohistochemical expression of b-catenin and of the two main mismatch repair proteins, MLH1 and MSH2. No loss of heterozygosity at APC was detected. We found mutations in b-catenin and p53 in 4/21 (19%) and 5/21 (24%) cases respectively, b-catenin protein accumulation in 14/21 cases (67%), microsatellite instability in 17/21 cases (81%), of which eight resulted positive for high-level of microsatellite instability (in four cases associated with loss of MLH1/MSH2 immunostaining). No correlations between involved molecular pathway(s) and hepatoblastoma histotype(s) emerged. This study confirms that b-catenin deregulation is involved in sporadic hepatoblastoma and also suggests that mismatch repair defects and p53 mutations contribute to this rare liver cancer. Sporadic hepatoblastoma appears to be molecularly and phenotypically heterogeneous and may reflect different pathways of liver carcinogenesis.
Hepatoblastoma, a rare embryonic tumor in the general population, represents the most frequent malignant liver tumor in childhood, with an incidence of one new case per 1 million under 15 years of age, male predominance, 1 and median age at diagnosis of 1 year. Most hepatoblastomas develop sporadically, but the incidence of the disease rises up to 1000-2000 folds in children from kindreds with familial adenomatous polyposis 2 or BeckwithWiedemann syndrome. 3 Several studies indicate that alterations in the APC/b-catenin pathway, which result in Wnt signal activation, play a role in the pathogenesis of hepatoblastoma. In fact, double-hit inactivation of the APC gene has been demonstrated in familial adenomatous polyposis-associated hepatoblastoma. [4] [5] [6] [7] [8] Furthermore, mutations affecting the phosphorylation sites encoded in exon 3 of b-catenin (a mutation hot-spot in several epithelial cancers) have been detected in sporadic hepatoblastoma, where APC mutations seem to be rare. [4] [5] [6] [7] [8] Somatic mutations in exons 5-8 of the p53 gene, which encode the DNA-binding region where cancer-associated mutations most frequently occur, [9] [10] [11] are strongly implicated in the progression of the common adult form of liver cancer, hepatocellular carcinoma. No hepatoblastoma-associated p53 mutations have been reported thus far, 12 however the rare Li-Fraumeni syndrome, due to germline p53 mutations, 13, 14 predisposes to a wide spectrum of early-onset cancers, and hepatoblastoma has been reported in Li-Fraumeni syndrome. 13 Hepatoblastoma is not included in the spectrum of tumors associated with the hereditary nonpolyposis colorectal cancer syndrome, due to mismatch repair gene defects. However, reduced expression of the two main mismatch repair proteins, MLH1 and MSH2, and high-level microsatellite instability play a role in hepatocellular carcinoma. [15] [16] [17] No data on microsatellite instability status and on expression of mismatch repair proteins are available for hepatoblastoma.
To shed further light on the molecular alterations associated with hepatoblastoma, we analyzed a series of 21 sporadic hepatoblastoma cases for loss of heterozygosity at the APC locus, mutations in the b-catenin and p53 genes, microsatellite instability and immunohistochemical expression of b-catenin, MLH1 and MSH2.
Materials and methods

Patients and Tissue Samples
We retrieved a retrospective series of 21 sporadic hepatoblastoma cases from pediatric patients who, between 1995 and 1999, underwent partial hepatectomy (eight cases) or liver transplantation (13 cases) at the Department of Surgery, Liver Transplant Unit, Louvain Catholic University, St Luc Hospital, Bruxelles, Belgium. The cases who underwent partial hepatectomy were given preoperative chemotherapy (cisplatin and doxorubicin) according to the protocols of the Société Internationale d'Oncologie Pediatrique. 18 Guardians of the patients gave written informed consent to biomedical studies after verbal counseling. Thirteen patients were male, 8 female; ages ranged from 2 to 132 months. None of the cases had family history of familial adenomatous polyposis, Li-Fraumeni syndrome, hereditary nonpolyposis colorectal cancer or other hereditary cancer syndromes, none was associated with hemihypertrophy or other congenital abnormalities suggestive of Beckwith-Wiedemann syndrome, 19 and all resulted negative for hepatitis B virus infection. Cases were re-reviewed by a single pathologist (MP). Formalin-fixed/paraffin embedded tissue blocks were sectioned at 5 mm and lightly stained with hematoxylin-eosin. Each block contained representative tumor areas together with non-neoplastic adjacent liver parenchyma. Tumor and non-tumor areas from 1 to 3 serial sections, identified using an hematoxylin-eosin stained section, were manually microdissected into 1.5 ml polypropylene vials for DNA extraction, as described. 20 
Loss of Heterozygosity and Microsatellite Instability Analyses
For microsatellite typing we used a protocol consisting of a non-radioactive external PCR followed by a radioactive internal PCR, as described. 20 Microsatellite instability was blindly scored by three investigators. Loss of heterozygosity at the APC locus was investigated in matched normal/tumor DNA analyzing seven microsatellites (D5S644, D5S492, D5S82, D5S299, D5S346, D5S656, D5S404) and the common APC intragenic polymorphism c.1458 (Y486Y), studied by RsaI restriction fragment length polymorphism analysis. 21 Microsatellite instability was evaluated at the 5 loci recommended by the National Cancer Institute reference panel (BAT25, BAT26, D2S123, D3S1611, D5S346).
22 Microsatellite instability at Z2 loci was defined as high-level (MSI-H), at o2 loci as low-level (MSI-L), cases in which no instability was detected were considered microsatellite-stable.
Mutational Analyses
b-Catenin exon 3 and p53 exons 5-8 were screened by single-strand conformational polymorphism analysis. 20, 23 Direct sequencing of the positive samples was performed using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Primers and PCR conditions are available upon requests. Mutations at b-catenin codon 32 were confirmed by HinfI restriction fragment-length polymorphism assay, where the 140 base pairs PCR product yields fragments of 73, 60 and 7 base pairs if wild type and of 80 and 60 base pairs if mutated. To exclude PCR artefacts, all mutations were confirmed on both DNA strands and in duplicate experiments on separately extracted DNA samples. Due to lack of frozen samples, we could not investigate large b-catenin gene deletions, which may occur in hepatoblastoma. 5 
Immunohistochemistry
For immunohistochemistry 5 mm-thick sections were stained with antibodies against MLH1 (BD Pharmingen, clone G168-15, diluted 1:25), MSH2 (Oncogene, clone FE11, diluted 1:100) and b-catenin (Novocastra, clone 17C2, diluted 1:100). Reactions were developed using the EnVision kit system (K4001, Dako, Glostrup, Denmark), with diaminobenzidine as chromogen. In control sections the specific primary antibody was omitted or replaced with non-immune serum or isotype-matched immunoglobulins (Dako). In one case, sections for immunohistochemistry were not available, due to exhaustion of the paraffin-embedded block. Cases were considered negative for MLH1 and/or MSH2 staining only in the presence of positive internal control (normal bile duct epithelium).
Results
The institutional series of 21 sporadic hepatoblastoma cases collected between 1995 and 1999 at the Liver Transplant Unit of the Louvain Catholic University in Bruxelles was pathologically reviewed and subclassified according to Ishak et al 24 as epithelial (n ¼ 11, of which seven with fetal pattern and four with embryonal/fetal pattern) and mixed epithelial/mesenchymal (n ¼ 10, of which one is with teratoid features) ( Table 1 ).
All cases were analyzed for loss of heterozygosity at the APC locus and were heterozygous at a minimum of four of eight tested markers. No evidence of loss of heterozygosity was found.
We detected three different b-catenin mutations in 4/21 cases (19%), namely: a GAC-GGC transition at codon 32 (D32G) in cases #4 and #12; a GTT-ATT transition at codon 22 (V22I) in case #19; a CAA-TAA nonsense mutation (Q27X) at codon 27 in case #3. With regard to histotype, b-catenin mutations were detected in 2/11 (18%) epithelial and 2/10 (20%) mixed epithelial/mesenchymal cases (Tables 1 and 2 ). Immunohistochemistry revealed b-catenin immunostaining in 14/21 cases (67%), which included three of the four cases mutated in the b-catenin gene (Table 1, Figure 2a and b). Accumulation of b-catenin was detected in both epithelial (8/11, 73%) and mixed epithelial/ mesenchymal (6/10, 60%) cases, being preferentially localized in embryonal and mesenchymal areas, respectively (Table 1) .
We detected 10 different p53 mutations in 5/21 cases (24% ; Tables 1 and 2 ). These included 1 missense mutation in exon 5 (T140I, case #8); 1 nonsense mutation in exon 6 (Q192X, case #8); 3 missense mutations in exon 7 (R248W, case #3; H233Y, cases #4 and #8; C242Y, case #13); 3 missense mutations in exon 8 (G279E, case #3; E271K, case #8; P292S, case #13). In addition, we found two silent mutations in exon 7 (I251I, case #4 and R249R, case #16). Multiple p53 mutations were detected in cases #8 (four mutations), #3, #4 and #13 (two mutations each). With regard to histotype, p53 mutations were detected in 3/11 (27%) epithelial cases (of which two also mutated inb-catenin) and in 2/10 (20%) mixed epithelial/mesenchymal cases (Table 1) .
Microsatellite instability, assessed at the 5 loci recommended by the National Cancer Institute reference panel, 22 was detected in 17/21 cases (81%) (Tables 1 and 2, Figure 1 ). According to Boland et al, 22 eight cases were defined as high-level microsatellite instability, nine as low-level microsatellite instability, and four as microsatellite-stable. With regard to histotype, microsatellite instability was detected in 10/11 (91%) epithelial cases, and in 7/10 (70%) mixed epithelial/mesenchymal cases, of which five and three were high-level microsatellite instability, respectively.
We analyzed by immunohistochemistry MLH1 and MSH2 expression in seven of the eight high-level microsatellite instability-positive cases (one case could not be examined due to exhaustion of the block). Four cases showed loss of immunostaining: two resulted negative for MLH1, two revealed loss of both MLH1 and MSH2 (Tables 1  and 2 , Figure 2c-f) .
A possible role of preoperative chemotherapy in determining the detected hepatoblastoma-associated molecular alterations is unlikely, as mutations in b-catenin, p53, and microsatellite instability as well as alterations in b-catenin and MLH1 and MSH2 immunostaining were observed in both treated and untreated cases (Tables 1 and 2 ).
Discussion
Little is known about the molecular pathways that contribute to hepatoblastoma. 4 We studied a series of 21 sporadic hepatoblastomas collected at the Louvain Catholic University in Bruxelles. The cases were analyzed for loss of heterozygosity at the APC locus, mutations in the b-catenin, and p53 genes, b-catenin protein accumulation and microsatellite instability status. Cases determined as high-level microsatellite instability were further characterized for the expression of the MLH1 and MSH2 proteins by immunohistochemistry.
Absence of loss of heterozygosity at the APC locus confirms literature reports suggesting that APC gene alterations are not implicated in sporadic hepatoblastoma. 7, 25 Mutational analysis of b-catenin exon 3, which encodes a region rich in serine and threonine residues that serve as targets of phosphorylation by GSK-3b, 8 revealed point mutations in 4/21 (19%) cases. These mutations may influence b-catenin stability.
5,26
The detection of b-catenin mutations and/or protein accumulation in the majority of our hepatoblastoma cases (15/21; 71%) confirms that Wnt signal activation is implicated in the pathogenesis of sporadic hepatoblastoma. [5] [6] [7] Our results are in agreement with the studies of Koch et al, 5 ,27 who detected b-catenin point mutations in 22 and 25% of their sporadic hepatoblastoma cases, while Taniguchi et al reported a slightly higher percentage (33%) of mutated cases. 28 As reported by Takayasu et al, 25 we observed that the hepatoblastoma cases with b-catenin protein accumulation were much more numerous than the cases with identified b-catenin mutations. In this respect it should be noted that we could not investigate large b-catenin gene deletions, which are known to occur in hepatoblastoma. 5, 27, 28 Furthermore, we cannot exclude alterations in Wnt regulators acting upstream of b-catenin, 29 such as AXIN1 and AXIN2, implicated in hepatoblastoma cases negative for mutations in the b-catenin gene but positive for b-catenin protein accumulation. 28, 30 With regard to correlations with histology, it is noteworthy that b-catenin immunostaining tended to be more evident in embryonal and in mesenchymal areas in epithelial and in mixed epithelial/ mesenchymal hepatoblastoma, respectively. This is concordant with evidence suggesting that b-catenin activation interferes with developmental signals regulating early stages of hepatic differentiation. 7, 25 Literature data indicate that p53 mutations occur commonly in the progression of tumors with Wntsignaling activation. 31, 32 The report of hepatoblastoma in two Li-Fraumeni syndrome patients is thus far the only evidence suggesting an involvement of p53 in hepatoblastoma. 13 In the present study, we found somatic p53 mutations in 5/21 hepatoblastoma cases (24%) and four of these cases harbored multiple p53 mutations. All detected mutations are listed in the International Agency for Cancer Research p53 mutation database (http:// www.iarc.fr/p53) in association with a variety of tumors. Interestingly, p53 Q192X and p53 C242Y, detected in two different hepatoblastoma cases, were previously found in hepatocellular carcinoma. Furthermore, p53 I251I, a silent mutation found in an hepatoblastoma case, was reported in both hepatitis B virus-positive and -negative hepatocellular carcinoma and also in hepatocellular carcinoma associated to aflatoxin exposure. The presence of somatic p53 mutations in hepatoblastoma suggests a possible role of pre-or peri-natal exposure to mutagens. Unfortunately, no information on course of pregnancy and weight at birth could be retrieved for our hepatoblastoma case series. It is also intriguing that we found microsatellite instability in the vast majority of our sporadic hepatoblastoma cases. In fact exposure to environmental toxicants/ carcinogens, particularly heavy metals, is correlated with microsatellite instability in adult cancers due to occupational exposure. 33, 34 In our hepatoblastoma series the high-and low-level microsatellite instability phenotypes did not appear to be specifically associated with b-catenin alterations, p53 mutations, and epithelial vs epithelial/mesenchymal histology. A role of preoperative chemotherapy in determining the observed genetic alterations is unlikely, as mutations and microsatellite instability were found in both preoperatively-treated and -untreated hepatoblastoma cases.
The role of microsatellite instability in liver cancer is still debated. Microsatellite instability has been reported in hepatocellular carcinoma arising in the context of chronic hepatitis and cirrhosis and also in non-fibrotic hepatocellular carcinoma. 16, 17 Previous studies indicate that Figure 1 Examples of microsatellite instability typings at D2S123, D5S346 and BAT26 in five hepatoblastoma cases (N: normal; T: tumor): case #1 shows microsatellite instability at D2S123 and D5S346; cases #16 and #10 show microsatellite instability at D2S123; case #12 does not show microsatellite instability at the tested loci; case #19 shows microsatellite instability at BAT26.
reduced expression of the two major mismatch repair proteins, MLH1 and MSH2, occurs in hepatocellular carcinoma, particularly in association with hepatitis C virus infection. 15 We found microsatellite instability in the vast majority of our sporadic hepatoblastoma cases. The high-level and low-level microsatellite instability phenotypes did not appear to be specifically associated with b-catenin alterations, p53 mutations and epithelial vs epithelial/mesenchymal histology. While lowlevel microsatellite instability could reflect inherent repeat instability and clonal expansion, high-level microsatellite instability, particularly when associated with loss of MLH1/MSH2 staining (as in four of our hepatoblastoma cases) suggests that mismatch repair defects could play a pathogenetic role. In conclusion our study suggests that b-catenin activation, p53 gene mutations and loss of mismatch repair function may contribute, either independently or in synergy, to the development of sporadic hepatoblastoma. The molecular alterations affecting these pathways do not appear to correlate with clinical-pathological features, with the exception of preferential b-catenin accumulation in embryonal and mesenchymal areas. Sporadic hepatoblastoma seems to represent a molecularly heterogeneous cancer, which could reflect different molecular mechanisms of progression.
